PMID- 24884787
OWN - NLM
STAT- MEDLINE
DCOM- 20141031
LR  - 20221207
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 13
DP  - 2014 May 24
TI  - A pilot three-month sitagliptin treatment increases serum adiponectin level in 
      Japanese patients with type 2 diabetes mellitus--a randomized controlled trial 
      START-J study.
PG  - 96
LID - 10.1186/1475-2840-13-96 [doi]
AB  - BACKGROUND: The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including 
      sitagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM). 
      Adiponectin, an adipocyte-derived circulating protein, has anti-atherosclerotic 
      and anti-diabetic properties and is effectively elevated in bloodstream by 
      thiazolidinediones, an insulin sensitizer. However, the effect of sitagliptin 
      treatment on serum adiponectin level in T2DM has not fully elucidated in Japanese 
      T2DM patients. The aim of the present study was to examine the effect of 
      sitagliptin treatment on serum adiponectin levels in T2DM subjects. METHODS: 
      Twenty-six consecutive Japanese T2DM outpatients were recruited between April 
      2011 and March 2013, and randomized into the control (conventional treatment, 
      n = 10) group and sitagliptin treatment group (n = 16). Serum adiponectin was 
      measured by enzyme-linked immunosorbent assay. RESULTS: Indices of glycemic 
      control, such as hemoglobin A1c, glycated albumin, and 1.5-anhydro-D-glucitol, 
      were significantly improved after the three-month treatment in both the control 
      and sitagliptin groups. Serum adiponectin level was significantly increased in 
      sitagliptin group from 6.7 +/- 0.8 to 7.4 +/- 1.0 mug/mL without change of body mass 
      index (p = 0.034), while serum adiponectin level was not altered in the control 
      group (p = 0.601). CONCLUSION: In Japanese T2DM patients, serum adiponectin level 
      was elevated by three-month treatment with sitagliptin without change of body 
      weight. TRIAL REGISTRATION: UMIN000004721.
FAU - Hibuse, Toshiyuki
AU  - Hibuse T
FAU - Maeda, Norikazu
AU  - Maeda N
AD  - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 
      2-2 B-5, Yamada-oka, Suita, Osaka 565-0871, Japan. 
      norikazu_maeda@endmet.med.osaka-u.ac.jp.
FAU - Kishida, Ken
AU  - Kishida K
FAU - Kimura, Takekazu
AU  - Kimura T
FAU - Minami, Tomoko
AU  - Minami T
FAU - Takeshita, Eriko
AU  - Takeshita E
FAU - Hirata, Ayumu
AU  - Hirata A
FAU - Nakagawa, Yasuhiko
AU  - Nakagawa Y
FAU - Kashine, Susumu
AU  - Kashine S
FAU - Oka, Akemi
AU  - Oka A
FAU - Hayashi, Masumi
AU  - Hayashi M
FAU - Nishizawa, Hitoshi
AU  - Nishizawa H
FAU - Funahashi, Tohru
AU  - Funahashi T
FAU - Shimomura, Iichiro
AU  - Shimomura I
LA  - eng
SI  - JPRN/UMIN000004721
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140524
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (ADIPOQ protein, human)
RN  - 0 (Adiponectin)
RN  - 0 (Biomarkers)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Pyrazines)
RN  - 0 (Triazoles)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adiponectin/biosynthesis/*blood
MH  - Aged
MH  - *Asian People/ethnology
MH  - Biomarkers/blood
MH  - Body Weight
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy/ethnology
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Pyrazines/*therapeutic use
MH  - Sitagliptin Phosphate
MH  - Time Factors
MH  - Treatment Outcome
MH  - Triazoles/*therapeutic use
PMC - PMC4049487
EDAT- 2014/06/03 06:00
MHDA- 2014/11/02 06:00
PMCR- 2014/05/24
CRDT- 2014/06/03 06:00
PHST- 2014/05/12 00:00 [received]
PHST- 2014/05/18 00:00 [accepted]
PHST- 2014/06/03 06:00 [entrez]
PHST- 2014/06/03 06:00 [pubmed]
PHST- 2014/11/02 06:00 [medline]
PHST- 2014/05/24 00:00 [pmc-release]
AID - 1475-2840-13-96 [pii]
AID - 10.1186/1475-2840-13-96 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2014 May 24;13:96. doi: 10.1186/1475-2840-13-96.